FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

DEA Proposes Placing MAB-CHMINACA in Schedule I

Feb. 1, 2018

The DEA plans to permanently designate the synthetic cannabinoid MAB-CHMINACA as a schedule I controlled substance after evaluating its potential for abuse and previous public health incidents.

The drug has no accepted medical use for treatment in the U.S. and has a high potential for abuse, the DEA said. The drug was temporarily placed in schedule I in 2016.

In 2014, the drug was associated with the hospitalization of 125 individuals in Louisiana and it has since been connected with over 1,400 adverse events, including seizures, comas, severe agitation, loss of consciousness, difficulty breathing and convulsions that sometimes resulted in death.

View today's stories